Novartis future growth prospects secured by industry-leading pipeline
(MENAFN Press) Dubai, United Arab Emirates -
Novartis today will provide an update on its leading Research and Development (R&D) pipeline and plans for turning these assets into commercial success to provide the basis for continued growth of the Group through 2017. Continuing R&D productivity in the Pharmaceuticals Division has fueled an industry-leading pipeline with 139 projects in clinical development with more than 73 New Molecular Entities (NMEs) across a multitude of disease areas. Highlights include RLX030 and LCZ696 in heart failure as well as AIN457 in psoriasis and multiple sclerosis. In addition, the company will showcase a comprehensive early and late-stage pipeline of novel oncology compounds.
"As a science-driven company, Novartis is focused on innovation to address unmet medical needs for patients around the world." said Joseph Jimenez, CEO of Novartis. "As a result, our leading pipeline in all phases of development positions us well for continued future growth."
Leading pipeline positions Pharmaceuticals for sustained future growth
Novartis Group continues to lead the industry with 56 new approvals in the US, Europe, Japan and China since 2007. In 2012 alone, the Pharmaceuticals division has received 9 approvals or positive recommendations to date.
Novartis Pharmaceuticals has established a strong foundation for the company's ongoing growth based on currently marketed products. In addition for the next 12 months, Pharmaceuticals expects data read-out on 13 pivotal studies, 9 filings and 7 regulatory decisions. For the following 13 to 24 months, strong pipeline newsflow is expected to continue with a further 11 pivotal trials read-out, 11 filings and 10 regulatory decisions.
As evidenced by the recent launches of Afinitor, Seebri Breezhaler, Jakavi and Signifor, Novartis has a proven track record of bringing innovative products to market. With the current marketed portfolio, Pharmaceuticals is expected to grow from the second half of next year despite loss of exclusivity on mature brands like Diovan, Zometa and Aclasta.
Oncology aims for continued growth through Glivec patent expiry
The Novartis Oncology portfolio has delivered approvals for 6 indications including 2 new molecular entities so far this year and anticipates continued growth over the next five years. One of the major growth drivers, Afinitor, has five indications already approved and has the potential to exceed sales of USD 2 billion in breast cancer alone by 2017. In addition, launches of Jakavi and the planned launches of pipeline projects such as BKM120 for various tumors and LDK378 in lung cancer have the potential to contribute more than USD 1 billion in sales by 2017.
Tasigna: "Path to Cure" - a potential paradigm shift in CML treatment
Novartis has transformed Ph chronic myeloid leukemia (CML) to a treatable, chronic condition and is again on the way to redefine what is possible in CML. The new goal is for patients to live free of drug therapy once they have achieved long-term response to treatment. Tasigna, a potent 2nd generation targeted therapy for CML, has demonstrated a reduced risk of progression and deeper and more sustained molecular response than Glivec. Based on these advances, as well as advances in molecular response monitoring, in 2013 the company plans to initiate Tasigna clinical trials to explore the goal of achieving sustained treatment-free remission in patients living with CML. If positive, this could lead to a major paradigm shift in CML treatment.
PRISM: a broad scale program for BKM120, a pan-PI3K inhibitor
Novartis has initiated a broad scale clinical development program named PRISM for its leading PI3K inhibitor BKM120 across multiple indications, both as a single agent and in combination with other therapeutic agents in various breast cancer settings, as well as other indications.
The company also plans to initiate pivotal studies of LDK378, an ALK inhibitor that has shown potent activity in patients with Alk non-small cell lung cancer (NSCLC) as well as activity on brain metastases, in December 2012. Additional trials planned for 2013 and regulatory filings expected to begin in 2014 if trials are successful.
Next wave of promising pipeline newsflow
Strong data in heart failure
Recently presented data for RLX030 show that patients receiving a single infusion of RLX030 had both short-term and long-term benefits. In the short term, RLX030 treated patients had improved heart failure symptoms such as dyspnea (shortness of breath) and edema, in addition to having a shorter stay in the hospital. The long term benefits of RLX030 resulted in a statistically significant 37% reduction in cardiovascular mortality and all-cause mortality.
Furthermore, fewer patients treated with RLX030 had worsening of heart failure as measured on day 5 and day 14 after treatment. Worsening of heart failure during hospitalization was defined as intensification of intravenous therapy or mechanical ventilator or circulatory support. Based on these findings of the RELAX-AHF study, Novartis plans to initiate regulatory filings for RLX030 in early 2013 in the US and Europe.
Comprehensive clinical program in COPD
Novartis is also progressing its comprehensive clinical program in respiratory to meet the needs of patients with chronic obstructive pulmonary disease (COPD). QVA149 has the potential to establish a new standard of care for patients with COPD, preventing exacerbations and showing improvement in bronchodilation compared to placebo and current standard of care. Across numerous clinical studies, QVA149 enables the limited use of inhaled corticosteroids (ICS) as rescue medications as recommended by the GOLD treatment guidelines for COPD.
IL-17 as promising target in psoriasis and other indications
Clinical data for AIN457, a highly effective novel IL-17 inhibitor, across multiple disease areas including psoriasis, ankylosing spondylitis, rheumatoid arthritis and multiple sclerosis were presented. In Phase II clinical studies, AIN457 has shown rapid improvement of psoriasis signs and symptoms in patients with moderate to severe psoriasis. Phase III studies for AIN457 in this setting are ongoing with regulatory filings expected to start in late 2013. In addition, the company is investigating AIN457 across multiple indications including multiple sclerosis.
Innovative initiatives showcase how to accelerate development; managing more projects at stable cost level
The discovery process in the Novartis Institute of BioMedical Research (NIBR) focuses on disorders where there is unmet medical need and good mechanistic understanding. This approach has increased the success rate from pre-clinical through Phase 2 trials to more than 20%, three times the industry average. Companion diagnostics and biomarkers, especially in oncology, where most Phase I and II trials have patient selection markers included, have enabled early patient selection for clinical trials, reducing overall development timelines and costs. As a result, Novartis has shown greater than average pipeline return on investment achieving highest average annual peak sales of first launched productsamongst industry.
In addition, Novartis is striving to increase efficiency and productivity to manage more projects while keeping costs at a stable level. Introducing novel technologies and methods reduce recruitment time and trial costs, while improving study quality and patient comfort and safety. These include mobile field monitoring, continuous manufacturing and Telehealth. In addition, through a research initiative with Walgreens in the US, clinical trials will provide more real-world evidence and lower access barriers for participants.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2011, the Group's continuing operations achieved net sales of USD 58.6 billion, while approximately USD 9.6 billion (USD 9.2 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 127,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.
MENA News Headlines
|Mar 12 2014||ME airlines to post USD2.2b profit in 2014 ,MENAFN|
|(MENAFN) The International Air Transport Association (IATA) said that airlines in the Middle East are expected to register a combined profit of USD2.2 billion this year, Arabian Business ...|
|Mar 12 2014||Qatar's Ezdan buys over 20 percent of IHG shares ,MENAFN|
|(MENAFN) Qatar"s Ezdan Holding said that it has purchased over 20 percent of Islamic Holding Group (IHG) shares, The Peninsula Qatar reported.
Chairman of Ezdan Holding Group said: "Acquiring such ...|
|Mar 12 2014||FCC wins USD701m Doha Metro contract ,MENAFN|
|(MENAFN) FCC announced that it won a USD701.5 million contract to build a section of Doha Metro red line, The Peninsula Qatar reported.
The consortium led by FCC also includes Archirodon from ...|
|Mar 12 2014||Emirates launches Boston flight ,MENAFN|
|(MENAFN) UAE-based Emirates has launched a non-stop flight to Boston, US, Khaleej Times reported.
Emirates airline president said: This is a fantastic day for Emirates. We are so pleased to be ...|
|Mar 12 2014||UAE's Etisalat signs agreement with Tata ,MENAFN|
|(MENAFN) UAE's Etisalat has announced the signing of a partnership agreement with Tata Communications that will focus on media and communication vertical segment, according to the Emirates ...|
|Mar 12 2014||Dewa invests USD14b in energy-efficiency projects ,MENAFN|
|(MENAFN) UAE-based Dewa managing director and chief executive said that the authority has an estimated investment of USD14.1 billion in energy-efficiency projects and actively promotes conservation, ...|
|Mar 12 2014||US firm Hill to recover USD10 m of Libyan debt ,MENAFN|
|(MENAFN) US construction management firm Hill International has now recovered USD10 million of USD60 million invoice owed for work in conflict-ridden Libya, the company said as it announced its 2013 ...|
|Mar 12 2014||Getafe confirm Contra as new coach ,Kora|
|(MENAFN - Kora) Garcia lost his job after a run of 12 La Liga matches without a win left the side precariously placed just one point above the bottom three.
A matter of hours after announcing his ...|
|Mar 12 2014||Dubai's Arabtec to build million home in Egypt ,MENAFN|
|(MENAFN) Dubai-based Arabtec plans to build one million homes in Egypt in a USD40 billion deal that is expected to open the doors to a politically-inspired Gulf investment, according to Arabian ...|
|Mar 12 2014||La Liga Wrap: Strugglers Rayo, Malaga pick up valuable away wins ,Kora|
|(MENAFN - Kora)
In an action-packed affair at Anoeta, the hosts took the lead after just two minutes when Inigo Martinez headed home a dangerous inswinging delivery from Ruben Pardo.
Their lead ...|
|Mar 12 2014||Seedorf upbeat over Milan chances ,Kora|
|(MENAFN - Kora) Seedorf's men face a stiff task at Vicente Calderon on Tuesday after suffering a 1-0 defeat in the first leg of their last-16 tie at San Siro last month.
Milan occupy a mid-table ...|
|Mar 12 2014||UEFA Europa League Preview: AZ v Anzhi ,Kora|
|(MENAFN - Kora) Owner Suleyman Kerimov withdrew the majority of his funding from Anzhi last year, leading to a mass exodus of players that saw them slide down the Russian Premier League table.
|Mar 12 2014||JD.com valued at USD20 b in IPO ,MENAFN|
|(MENAFN) An initial public offering (IPO) has been proposed for JD.com, the Chinese ecommerce site backed by Saudi Arabia's Prince Alwaleed bin Talal, at USD20 billion worth in the second quarter of ...|
|Mar 12 2014||Championship Wrap: Reading stun Leeds, Blackpool end barren streak ,Kora|
|(MENAFN - Kora) Exactly a year to the day since his departure from Reading, McDermott watched his Leeds side follow up Saturday's 5-1 home thrashing at the hands of Bolton Wanderers with another poor ...|
|Mar 12 2014||Schumacher showing 'small, encouraging' signs ,Kora|
|(MENAFN - Kora) The seven-time Formula One world champion has been in a medically induced coma for over two months after suffering head trauma in a skiing accident on December 29.
Last week, it ...|
|Mar 12 2014||Pillay Urges Halt to Attacks Targeting Civilians ,Qatar News Agency|
|(MENAFN - Qatar News Agency) UN High Commissioner for Human Rights Navi Pillay expressed deep concern on Tuesday that civilians in South Darfur, Sudan, have been bearing the brunt of recent attacks. ...|
|Mar 12 2014||Libyan PM Zeidan Dismissed as Oil Tanker 'Breaks Blockade' ,Qatar News Agency|
|(MENAFN - Qatar News Agency) Libya's parliament has dismissed Prime Minister Ali Zeidan after a tanker laden with oil from a rebel-held port reportedly broke through a naval blockade. MPs called a ...|
|Mar 12 2014||Bulgaria's President : Great Prospects for Further Cooperation with Qatar ,Qatar News Agency|
|(MENAFN - Qatar News Agency) Bulgaria's President Rosen Plevneliev said that there is a great prospect for further cooperation between his country and the State of Qatar in various fields. Speaking ...|
|Mar 12 2014||Nsour:Israel Apologizes Over Zeiter Killing ,Qatar News Agency|
|(MENAFN - Qatar News Agency) Israel has officially apologized for the killing of Jordanian judge Raed Zeiter who was shot dead by Israeli soldiers on Monday after he had crossed the King Hussein ...|
|Mar 12 2014||Israeli Airstrike Kills 3 Palestinians in Southern Gaza ,Qatar News Agency|
|(MENAFN - Qatar News Agency) An Israeli airstrike killed three Palestinians in the southern Gaza Strip on Tuesday, an official said.
Gaza Ministry of Health spokesman Ashraf al-Qidra said that ...|